Deferoxamine in ICH

Deferoxamine: iron chelator that decreases ability of free iron in brain tissue to cause oxidative injury

Phase I Study of deferoxamine mesylate (DFO) in patients with ICH demonstrated tolerability of doses up to 62mg/kg/day to max of 6000 mg/d x 5 days without major safety concerns.

Pilot trial of same dosage x 3 days shows lower perihematomal edema in patients treated with deferoxamine.

Phase 2 trial at this dose stopped due to increased occurrence of ARDS.

Recruitment for lower-dose phase 2 iDEF trial ongoing.


Burns, J., Fisher, J. and Cervantes-Arslanian, A. (2018). Recent Advances in the Acute Management of Intracerebral Hemorrhage. Neurosurgery Clinics of North America, 29(2), pp.263-272.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: